Merck Serono, Apitope to Collaborate on MS Drug

Apitope International NV signed an accord giving exclusive worldwide rights to Merck Serono to develop and commercialize ATX-MS-1467, a peptide therapeutic that has completed an initial clinical study in patients with multiple sclerosis, Merck Serono said.
Fox Business